^
    Back
    Association details:
    Biomarker:RET fusion
    Cancer:Thyroid Gland Papillary Carcinoma
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

    Published date:
    05/19/2021
    Excerpt:
    109 patients enrolled...patients with RET fusion positive papillary thyroid cancer had a PR...Cabozantinib is active in patients with relapsed refractory OS...PRs were also seen in select carcinomas.
    DOI:
    10.1200/JCO.2021.39.15_suppl.10010
    Trial ID:
    ADVL1622
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cold Spring Harb Mol Case Stud
    Title:

    Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma

    Excerpt:
    Preclinical study on PTC cell-line with RET fusion showed that XL184 (cabozantinib) is more potent in inhibiting cell growth…
    DOI:
    10.1101/mcs.a002568